The economic impact of HA-1A (Centoxin) against endotoxin.
Monoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative sepsis and/or septic shock.  However, the acquisition costs of the antibody products are expected to be in the range of $US3500 to $US4000 per course of therapy and precise identification of patients who will benefit may be difficult.  Therefore, the economic impact of these antibodies will be significant.  We have performed a model cost-effectiveness and cost-benefit analysis specific to our institution based on previously reported mortality figures.  Our data suggest that the cost-effectiveness of HA-1A (Centoxin) will be comparable with that of a variety of commonly used medical interventions, but will produce an incremental increase in costs of at least $US7000 per patient because of the acquisition cost of the drug, as well as an increase in numbers of survivors whose hospitalisation will be prolonged.
Barriere
S L
SL
University of California, Los Angeles, Center for the Health Sciences.
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004731:Endotoxins / Q000009:adverse effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000401:mortality; D017048:Health Care Costs; D006801:Humans; D007902:Length of Stay; D012189:Retrospective Studies; D012772:Shock, Septic / Q000188:drug therapy / Q000401:mortality